{
    "clinical_study": {
        "@rank": "164972", 
        "acronym": "ARTES", 
        "brief_summary": {
            "textblock": "To review the safety and efficacy of injections with Ozurdex (700 \u03bcg dexamethasone) in\n      clinical practice management of patients with DME."
        }, 
        "brief_title": "Retrospective Trial on the Efficacy and Safety of Intravitreal Ozurdex in Patients With Diabetic Macular Edema.", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Macular Edema", 
        "condition_browse": {
            "mesh_term": [
                "Edema", 
                "Macular Edema"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults (\u226518 years) with diabetes\n\n          -  DME in the study eye (if both eyes have DME both eyes will be included in analysis)\n\n          -  BCVA minimum of 20/200 (35 letters)\n\n          -  Central Macular Thickness (CMT) \u2265300 \u00b5m\n\n          -  Patients with DME who were treated with Ozurdex at least twice (baseline is before\n             the first Ozurdex injection).\n\n          -  Follow up of at least 6 months after the last Ozurdex injection given\n\n          -  Complete records including BCVA (OCT and Fluorescein Angiography (FA) if available)\n             throughout the follow up\n\n        Exclusion Criteria:\n\n          -  Patients with ME not secondary to Diabetes Mellitus (DM).\n\n          -  Presence of other retinopathies (AMD, RVO) or visually significant ocular morbidity\n             (e.g. advanced glaucoma, corneal opacity)\n\n          -  Previous ocular trauma or surgery other than cataract extraction\n\n          -  Intravitreal triamcinolone \u22646 months before baseline\n\n          -  Intravitreal bevacizumab, ranibizumab, or pegaptanib <1 months before baseline\n\n          -  Marked intraocular pressure (IOP) elevation in response to any previous steroid\n             treatment\n\n          -  Ocular Hypertension (OHT) in the study eye(s)\n\n          -  IOP >23 mm Hg without antiglaucoma medication\n\n          -  IOP >21 mm Hg with one antiglaucoma medication\n\n          -  Use of 2 or more antiglaucoma medications\n\n          -  Glaucoma - Visual Fields (VF) defect > 4 dB"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "300-400 patients who have received at least 2 Ozurdex injections for the treatment of DME,\n        were followed for at least 6 months after the last injection and with a minimal BCVA of\n        20/200 at baseline (before Ozurdex treatment)."
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02121197", 
            "org_study_id": "ECR-RET-2014-07"
        }, 
        "intervention": {
            "intervention_name": "Ozurdex", 
            "intervention_type": "Drug", 
            "other_name": "Dexamethasone"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Macular Diabetic Edema", 
            "Ozurdex", 
            "Retrospective", 
            "European", 
            "Intra-vitreal injections"
        ], 
        "lastchanged_date": "April 22, 2014", 
        "number_of_groups": "1", 
        "official_title": "A Collaborative Retrospective Trial on the Efficacy and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients With Diabetic Macular Edema (DME). THE EUROPEAN DME REGISTRAR STUDY (ARTES)", 
        "overall_contact": {
            "email": "mcosta@aibili.pt", 
            "last_name": "Miguel Costa, MSc", 
            "phone": "+351239480142"
        }, 
        "overall_official": {
            "affiliation": "Tel-Aviv Sourasky Medical Center", 
            "last_name": "Anat Loewenstein, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Portugal: Health Ethic Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage of patients with Best Corrected Visual Acuity (BCVA) from baseline to 4 - 6 months after last injection, with comparison between early (<9 month duration of DME) vs late (\u22659 month duration of DME), and na\u00efve vs previously treated patients.", 
            "safety_issue": "Yes", 
            "time_frame": "6 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02121197"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Association for Innovation and Biomedical Research on Light and Image", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Association for Innovation and Biomedical Research on Light and Image", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}